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. Mismatch between baseline LDL-C levels at trial entry and range of lipid-related high cardiovascular risk (red zone)
Baseline LDL-C in the trials listed on the right Reprinted from The Lancet, Vol. number 2, Martin, M.J., Hulley, S.B., Browner, W.S., Kuller, L.H. & Wentworth, D., Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men, 933-6, Copyright (1986) , with permission from Elsevier. 
All trials in the normal/borderline risk zone for TG
Baseline TG in the trials listed on the right
The mismatch between baseline TG in the trials and TG-related risk is shown in reference to ischemic (coronary) heart disease outcomes (top panel, middle graph). The same concept may be applied to other cardiovascular outcomes. Baseline HDL-C in the trials listed on the right Trials in "true" dyslipidemic patients are urged in order to reconsider comprehensive lipid management as a means to reduce residual cardiovascular risk -Supplemental v1.0 Table S1. Data of cardiovascular LDL-C trials included in Figure 2 (meta-regression analysis) 
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